The Yin and Yang of Targeting KLRG1 + Tregs and Effector Cells

The literature surrounding KLRG1 has primarily focused on NK and CD8 T cells. However, there is evidence that the most suppressive Tregs express KLRG1. Until now, the role of KLRG1 on Tregs has been mostly overlooked and remains to be elucidated. Here we review the current literature on KLRG1 with a...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 894508
Main Authors Borys, Samantha M, Bag, Arup K, Brossay, Laurent, Adeegbe, Dennis O
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 29.04.2022
Subjects
Autoimmunity
cancer
CD8-Positive T-Lymphocytes
immune modulation
Immunology
KLRG1
regulatory T cells (T reg)
T-Lymphocytes, Regulatory
Treg targeting
regulatory T cells (T reg)
cancer
Treg targeting
immune modulation
KLRG1
Online AccessGet full text

Cover

More Information
Summary:The literature surrounding KLRG1 has primarily focused on NK and CD8 T cells. However, there is evidence that the most suppressive Tregs express KLRG1. Until now, the role of KLRG1 on Tregs has been mostly overlooked and remains to be elucidated. Here we review the current literature on KLRG1 with an emphasis on the KLRG1 Treg subset role during cancer development and autoimmunity. KLRG1 has been recently proposed as a new checkpoint inhibitor target, but these studies focused on the effects of KLRG1 blockade on effector cells. We propose that when designing anti-tumor therapies targeting KLRG1, the effects on both effector cells and Tregs will have to be considered.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
Reviewed by: Ana Izcue, University Hospital RWTH Aachen, Germany; Michael Delacher, Johannes Gutenberg University Mainz, Germany
Edited by: Luca Gattinoni, Leibniz Institute for Immunotherapy (LIT), Germany
These authors have contributed equally to this work
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.894508